Leo Schoonover

The meeting was convened for the IRB 2 committee; however, a quorum was not present. Consequently, no official actions were taken, and no educational activities occurred during the session.

The committee held an educational session regarding data registry types, sources, confidentiality, and related misconceptions. Regarding protocol reviews, the committee approved a modification to the REPRIEVE A5332 study, which involved an increase in participant compensation. Additionally, the committee reviewed the Egrifta Long Term Observational Study, involving changes in principal investigator and research coordinator personnel, and requested further information regarding FDA recommendations on the study's continuation due to low enrollment.

The committee discussed business items including internal administrative processes and CITI certifications. The primary focus involved a continuing review of a study on cancer burden among adults from the Hispanic Community Health Study, which was formally approved. The committee also reviewed a multicenter AIDS and women's health study, for which no vote was taken due to outstanding team responses regarding language requirements and emergency safety measures for participants. Additional research protocols were acknowledged for informational purposes, including several expedited reviews and project closures.

The committee held an initial review for three research studies. The first study on childhood sexual abuse and posttraumatic stress symptoms was approved contingent upon receiving required documentation. The second study regarding a culturally adapted stress management intervention for prostate cancer patients was approved pending additional patient recruitment details and protocol modification approval. The third study concerning hospital quality and maternal and infant outcomes was also approved. Additionally, there was a presentation regarding IRB manager updates.

The committee focused on providing education regarding protocol-specific justifications for research involving vulnerable populations and consent waivers. They also reviewed and approved three specific protocols: modifications to an HIV-1 clinical trial regarding contraceptive restrictions and assay endpoints, a notification of clinical supply labeling errors for a different HIV-1 study, and an initial review of a new clinical study regarding a novel antivenom for coral snake bites, which included detailed regulatory assessments for the inclusion of children, pregnant women, and prisoners.